ATHOS-3: an international, multicenter, randomized, double-blind, placebo-controlled trial1,2
GIAPREZA was tested in adults with septic or other distributive shock who remained hypotensive despite fluid resuscitation and standard of care vasopressor therapy. GIAPREZA was tested against placebo, both in addition to background standard of care vasopressors.1,a
ATHOS-3 trial design
Abbreviation: MAP, mean arterial pressure.
aGIAPREZA and placebo were studied in conjunction with norepinephrine, epinephrine, dopamine, phenylephrine, and vasopressin.1
bTreatment allowed up to Day 7. Day 28 (+/- 2 days) follow-up determined safety events that occurred between Day 7 and Day 28.2